

DIN EN ISO 14155:2012-01 (E)

Clinical investigation of medical devices for human subjects - Good clinical practice (ISO 14155:2011 + Cor. 1:2011)

Contents		Page
Foreword		4
1	Scope	5
2	Normative references	5
3	Terms and definitions	6
4	Ethical considerations	11
4.1	General	11
4.2	Improper influence or inducement	12
4.3	Compensation and additional health care	12
4.4	Responsibilities	12
4.5	Communication with the ethics committee (EC)	12
4.5.1	General	12
4.5.2	Initial EC submission	12
4.5.3	Information to be obtained from the EC	13
4.5.4	Continuing communication with the EC	13
4.5.5	Continuing information to be obtained from the EC	13
4.6	Vulnerable populations	13
4.7	Informed consent	14
4.7.1	General	14
4.7.2	Process of obtaining informed consent	14
4.7.3	Special circumstances for informed consent	14
4.7.4	Information to be provided to the subject	15
4.7.5	Informed consent signature	17
4.7.6	New information	17
5	Clinical investigation planning	18
5.1	General	18
5.2	Risk evaluation	18
5.3	Justification for the design of the clinical investigation	18
5.4	Clinical investigation plan (CIP)	18
5.5	Investigator's brochure (IB)	19
5.6	Case report forms (CRFs)	19
5.7	Monitoring plan	19
5.8	Investigation site selection	19
5.9	Agreement(s)	19
5.10	Labelling	19
5.11	Data monitoring committee (DMC)	20
6	Clinical investigation conduct	20
6.1	General	20
6.2	Investigation site initiation	20
6.3	Investigation site monitoring	20
6.4	Adverse events and device deficiencies	20
6.4.1	Adverse events	20
6.4.2	Device deficiencies	20
6.5	Clinical investigation documents and documentation	21
6.5.1	Amendments	21
6.5.2	Subject identification log	21

6.5.3	Source documents	21
6.6	Additional members of the investigation site team	21
6.7	Subject privacy and confidentiality of data	21
6.8	Document and data control	22
6.8.1	Traceability of documents and data	22
6.8.2	Recording of data	22
6.8.3	Electronic clinical data systems	22
6.9	Investigational device accountability	23
6.10	Accounting for subjects	23
6.11	Auditing	23
7	Suspension, termination and close-out of the clinical investigation	24
7.1	Suspension or premature termination of the clinical investigation	24
7.1.1	Procedure for suspension or premature termination	24
7.1.2	Procedure for resuming the clinical investigation after temporary suspension	25
7.2	Routine close-out	25
7.3	Clinical investigation report	25
7.4	Document retention	26
8	Responsibilities of the sponsor	26
8.1	Clinical quality assurance and quality control	26
8.2	Clinical investigation planning and conduct	27
8.2.1	Selection of clinical personnel	27
8.2.2	Preparation of documents and materials	27
8.2.3	Conduct of clinical investigation	28
8.2.4	Monitoring	28
8.2.5	Safety evaluation and reporting	31
8.2.6	Clinical investigation close-out	31
8.3	Outsourcing of duties and functions	32
8.4	Communication with regulatory authorities	32
9	Responsibilities of the principal investigator	32
9.1	General	32
9.2	Qualification of the principal investigator	32
9.3	Qualification of investigation site	33
9.4	Communication with the EC	33
9.5	Informed consent process	33
9.6	Compliance with the CIP	33
9.7	Medical care of subjects	34
9.8	Safety reporting	35
	Annex A (normative) Clinical investigation plan (CIP)	36
	Annex B (normative) Investigator's brochure (IB)	43
	Annex C (informative) Case report forms (CRFs)	45
	Annex D (informative) Clinical investigation report	47
	Annex E (informative) Essential clinical investigation documents	52
	Annex F (informative) Adverse event categorization	59
	Bibliography	62
	Annex ZA (informative) Relationship between this European Standard and the Essential Requirements of EU Directive 93/42/EEC on Medical Devices	63
	Annex ZB (informative) Relationship between this European Standard and the Essential Requirements of EU Directive 90/385/EEC on Active Implantable Medical Devices	65